Alice Melao,  —

Articles by Alice Melao

Amicus’ AT-GAA Gets FDA’s Breakthrough Therapy Designation

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Amicus Therapeutics’ lead therapy candidate for the treatment of late-onset Pompe disease,  AT-GAA (ATB200/AT221). The FDA’s decision makes AT-GAA the first investigational therapy for Pompe disease to receive this regulatory status. It also further…

Amicus Announces Plans for Developing AT-GAA to Treat Pompe Disease

Amicus Therapeutics is planning to launch a pivotal trial to compare its investigational therapy AT-GAA (ATB200/AT221) to the current standard of care available for patients with Pompe disease. The new trial is expected to provide additional clinical data to support Accelerated Approval for AT-GAA by the U.S.